Dabrafenib clinical trials
Also written GSK2118436 and GSK-2118436A.
Includes 9 studies of Dabrafenib mesylate.
How each study uses dabrafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dabrafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 May 2013 · TAFINLAR · NDA 202806 (FDA, Drugs@FDA; as dabrafenib mesylate)
- European Union
- 26 Aug 2013 · Tafinlar · EMEA/H/C/002604 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
97 studies that test it; most in 2014 (13)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 9 |
| 2013 | 11 |
| 2014 | 13 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 59
Novartis Pharmaceuticals (19) · GlaxoSmithKline (16) · National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (4) · Massachusetts General Hospital (3) · Melanoma Institute Australia (2) · Memorial Sloan Kettering Cancer Center (2) · University of California, San Francisco (2)
Often tested with
Tested in the same studies.
Trametinib (58) · Nivolumab (8) · Pembrolizumab (6) · Vemurafenib (5) · Ipilimumab (4) · Binimetinib (4) · Palbociclib (4) · Pertuzumab (4)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Dabrafenib is the comparator. A study of two new drugs counts under both.
- 1Cabozantinib · ECOG-ACRIN Cancer Research Group · next primary completion Sep 2030
Reaching primary completion within a year · 9
Studies that test dabrafenib.
- Nov 2026Pediatric Long-Term Follow-up and Rollover StudyPhase 4 · Novartis Pharmaceuticals
- Dec 2026Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPhase 2 · Tianjin Medical University Second Hospital
- Dec 2026Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaPhase 2 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Mar 2027Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadPhase 2 · National Cancer Institute (NCI)
- Apr 2027Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationPhase 2 · M.D. Anderson Cancer Center
- Jun 2027Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
- Sep 2027Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaPhase 2 · National Cancer Institute (NCI)
- Nov 2027Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses dabrafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 97
- Dabrafenib and/or Trametinib Rollover StudyRecruitingPhase 4Novartis PharmaceuticalsNCT03340506Written as dabrafenib
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Dabrafenib
- Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasRecruitingPhase 2University of California, San FranciscoNCT07110246Written as Dabrafenib
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT07440290Written as Dabrafenib
- MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingPhase 1/2Ann & Robert H Lurie Children's Hospital of ChicagoNCT06712875Written as Dabrafenib, trametinib, nivolumab
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Dabrafenib
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886Written as Dabrafenib in combination with trametinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Dabrafenib+Trametinib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Dabrafenib
- Precision Cancer Therapy in Rare CancersRecruitingPhase 2Oslo University HospitalNCT06119789Written as Dabrafenib
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingPhase 2Tianjin Medical University Second HospitalNCT06739395Written as Dabrafenib
- Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaRecruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT06653517Written as Dabrafenib
- Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant AmeloblastomaNot yet recruitingPhase 3Shandong UniversityNCT06264778Written as Dabrafenib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Dabrafenib
- Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsRecruitingPhase 2Se Jun ParkNCT05876806Written as Dabrafenib
- A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)RecruitingPhase 2Olivia Newton-John Cancer Research InstituteNCT05182931Written as Dabrafenib 75 MG
- Melanoma Metastasized to the Brain and SteroidsRecruitingPhase 2Inge Marie SvaneNCT03563729Written as Dabrafenib
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439292Written as Dabrafenib Mesylate
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02196181Written as Dabrafenib Mesylate
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02224781Written as Dabrafenib Mesylate
See all 97 studies that test dabrafenib →
Given beside what is tested · 31 — dabrafenib is usual care or a partner of the new treatment
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07886905Written as Dabrafenib
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07506109Written as Dabrafenib
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as Dabrafenib
- A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2Immuneering CorporationNCT05585320Written as IMM-1-104 + dabrafenib (Treatment Group D)
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K MelanomaTerminatedPhase 2ECOG-ACRIN Cancer Research GroupNCT04527549Written as Dabrafenib mesylate
- PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04544111Written as Dabrafenib
- A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationActive, not recruitingPhase 1/2Pediatric Brain Tumor ConsortiumNCT04201457Written as Dabrafenib
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014Written as Trametinib and Dabrafenib
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid CancerCompletedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT03244956Written as Dabrafenib
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedPhase 1Novartis PharmaceuticalsNCT04294160Written as Dabrafenib
- A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaTerminatedPhase 3Novartis PharmaceuticalsNCT02967692Written as Dabrafenib
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsSuspendedPhase 1JS InnoPharm, LLCNCT04418167Written as Dabrafenib
- Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03026517Written as Dabrafenib
- Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01902173Written as Dabrafenib Mesylate
- BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedPhase 1/2Haukeland University HospitalNCT02872259Written as BGB324+dabrafenib and trametinib
- Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT04310397Written as Dabrafenib
- Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedPhase 1National Cancer Institute (NCI)NCT02097225Written as Dabrafenib
- MCS110 With BRAF/MEK Inhibition in Patients With MelanomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03455764Written as Dabrafenib
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Dabrafenib
- TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaCompletedPhase 2Universitair Ziekenhuis BrusselNCT04059224Written as Dabrafenib
Showing 20 of 31.
As the comparator · 1 — what is tested is compared with dabrafenib
Codes
What other systems call dabrafenib · ClinicalTrials.gg INT005899
- MeSH (NLM) C561627dabrafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QGP4HA4G1BDABRAFENIBConfirmed FDA, NLM, Wikidata
- RxNorm 1424911Confirmed FDA, Wikidata
- Wikidata Q3011604dabrafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82386DabrafenibOne source FDA
- DrugBank DB08912One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561627 | dabrafenib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QGP4HA4G1B | DABRAFENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1424911 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3011604 | dabrafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82386 | Dabrafenib | One source FDA |
| DrugBank | DB08912 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.